

**2018 First Aid for the USMLE Step 1
Corrections and Clarifications
June 1, 2018**

Despite our best efforts, errors do occur during the revision process. This list primarily addresses direct content errors that may create confusion. We also have listed selected clarifications. Please be aware, however, that this list does not represent the entire scope of additions, improvements, and clarifications made in the 2018 edition.

Red signifies specific text to be deleted.

Green signifies specific text to be added.

* signifies new errata addition since the March 20, 2018 publication.

We check every submission against your reference(s), authoritative references, and expert faculty to maximize clarity and accuracy. Please note that our goal is to provide a high-yield framework for optimal exam preparation and not a comprehensive textbook. If you were the first individual to submit a referenced correction or clarification to us at www.firstaidteam.com that appears in the errata or in the next edition of the book, you will receive a gift certificate in appreciation. Good luck with your studies!

–The First Aid/USMLE-Rx Team

CATEGORIES OF UPDATES

Major Corrections	Factual errors that could interfere with comprehension
Minor Corrections	Less significant errors that may cause confusion
Clarifications	The text is accurate but could be written more clearly, or minor formatting issues (misalignments, indents, etc) that may confuse

MAJOR CORRECTIONS

Page	Fact Name	Revision
40	DNA repair	In column 3 of the nonhomologous end joining row, delete “ and Fanconi anemia ” so the sentence reads “ Defective in ataxia telangiectasia. ” In column 3 of the homologous recombination row, add “ and in Fanconi anemia ” so the sentence reads “ Defective in breast/ovarian cancers with BRACA1 mutation and in Fanconi anemia. ”
42	Splicing of pre-mRNA	In the illustration, U2 snRNP should bind to Branch point , not AG . Move the green circle labeled “U2 snRNP” to behind the “A.”
81	Amino acids	In the essential row, the 9 essential amino acids are: phenylalanine, valine, tryptophan , threonine, isoleucine, methionine, histidine, leucine, lysine. Replace Tyrosine with Tryptophan .

112	Hypersensitivity types	In column 2 of the type I hypersensitivity row, change "and cytokines (eg, leukotrienes)" to "and other mediators (eg, leukotrienes)."
124	Bacterial structures	In column 1, " Glycocalyx " should be replaced with " Slime (S) layer. "
226	Common metastases	In the bone row, replace the second sentence in column 3 to read, " Small cell lung cancer is blastic, and non-small cell lung cancer is lytic. "
248	Drug names	In the "-limus" row under "other," change column 2 from " Calcineurin inhibitor " to " mTOR inhibitor " and change column 3 from "Everolimus, tacrolimus " to "Everolimus, sirolimus. "
284	Auscultation of the heart	In column 2 of the rapid squatting row, change "↑ intensity of AS , MR, and VSD murmurs" to "↑ intoensity of AR , MR, and VSD murmurs."
320	Thyroid development	In the last sentence in column 2, change "parafollicular cells (aka, C cells, produce Calcitonin) are derived from neural crest " to "parafollicular cells (aka, C cells, produce Calcitonin) are derived from endoderm. "
532	Levodopa/carbidopa	In the adverse events row, delete " from ↑ peripheral formation of catecholamines " from the first sentence, so it reads "Nausea, hallucinations, postural hypotension. "
535	Tramadol	In the mechanism row, replace "also inhibits 5-HT receptors " with "also inhibits the reuptake of norepinephrine and serotonin. "
542	Dissociative disorders*	Relocate the text, "May be accompanied by dissociative fugue (abrupt travel or wandering associated with traumatic circumstances)" from the dissociative identity disorder row to the dissociative amnesia row.
560	Opioid withdrawal and detoxification	Replace the entire entry for the naltrexone with the following " Naloxone, Opioid antagonist given IV, IM, or as nasal spray to treat acute overdose in unconscious individuals. Add a new row below Naloxone: Naltrexone, Used for relapse prevention once detoxified. Use naltrexone for the long trex back to sobriety. "
652	Response to high altitude	In line 5, change the parenthetical statement from "(binds to Hb causing left shift so that Hb releases more O ₂)" to "(binds to Hb causing right shift so that Hb releases more O ₂)."
595	Embryologic derivatives	In the neural crest row, delete " Parafollicular (C) cells of the thyroid. " In the endoderm row, change " thyroid follicular cells " to " parafollicular [C] cells of thyroid. "

MINOR CORRECTIONS

Page	Fact Name	Revision
9	Section I	The passing score for Step 1 changed from 192 to 194 . This change is effective as of January 1, 2018.

11	Section I	In paragraph 3 under Official NBME/USMLE Resources, change “The standard-paced format allows the user up to 65 minutes to complete each section...” This should read “up to 75 minutes”
72	Metabolism sites	In the cytoplasm row, delete " cholesterol ," and change " synthesis of steroids (SER) " to " synthesis of cholesterol (SER) ".
90	Ketone bodies	In column 2, change the last sentence to read, “ All of these processes lead to a build up of Acetyl CoA, which is shunted into ketone body synthesis. ”
101	Natural killer cells	Change the parenthetical in the last sentence to read, "(CD16 binds Fc region of bound IgG , activating the NK cell)." Change " Ig " to " IgG ."
109	Respiratory burst (oxidative burst)	In the second sentence of the last paragraph, delete " from proteoglycans ," so the sentence reads, "Oxidative burst also leads to K ⁺ influx, which releases lysosomal enzymes."
122	Therapeutic antibodies	Delete the entire row for " Daclizumab ."
125	Bacterial taxonomy	In column 1, change “Pleomorphic (no cell wall)” to "Pleomorphic (no rigid cell wall)."
154	<i>Pneumocystis jirovecii</i>	In the first paragraph, change “Diffuse, bilateral ground-glass opacities on CXR/CT ” to “Diffuse, bilateral ground-glass opacities on chest imaging .”
177	Common diseases of HIV-positive adults	In the <i>Pneumocystis jirovecii</i> row in the third column, change “‘Ground-glass’ opacities on CXR ” with “‘Ground-glass’ opacities on chest imaging .”
204	Hepatitis C therapy	Delete the sentence “ Ribavirin also used to treat RSV (palivizumab preferred in children) .” In the simeprevir row, change column 2 to read, “ Inhibits HCV protease (NS3/4A); prevents viral replication. ”
244	Drug reactions—endocrine /reproductive	In column 3 of the hyperprolactinemia row, delete “(more common in men).”
312	Ranolazine	In the mechanism row, change the last sentence from “Does not affect heart rate or contractility ” to “Does not affect heart rate or blood pressure .”
401	Coagulation and kinin pathways	The gray arrow for thrombin in the combined pathway should not point to factor IX in the contact activation (intrinsic) pathway; it should point to factor XI. Thrombin activates factors V, VIII, XI, XIII. It does not activate factor IX.

429	Microtubule inhibitors*	In the clinical use column of the vincristine, vinblastine row, delete “(vinblastine)” and “(vincristine)” so the text reads, “Solid tumors, leukemias, Hodgkin and non-Hodgkin lymphomas.”
444	Childhood musculoskeletal conditions	In the radial head subluxation (nursemaid’s elbow) row, change the last sentence to read “Injured arm held in extended/slightly flexed and pronated position.”
478	Myelin	In column 2, change the last sentence to read “In CNS (including CN II), myelin is synthesized by oligodendrocytes; in PNS (including CNs III-XII), myelin is synthesized by Schwann cells. ”
560	Opioid withdrawal and detoxification	In the naltrexone row, change “Long-acting opioid...” to “Long-acting opioid antagonist.... ”
609	Autonomic innervation of male sexual response	In the last paragraph of column 2, change “ Ejaculation —visceral and Somatic nerves” to “ Expulsion —visceral and Somatic nerves.”
628	Ovarian neoplasms	Delete the entire row for Endometrioma .
648	Cyanide poisoning	Delete “ cyanosis ” from the list of findings.

CLARIFICATIONS

Page	Fact Name	Revision
115	Autoantibodies*	In the 14th row of the table, in the autoantibody column, change “ Antimitochondrial 1° biliary cirrhosis ” to “ Antimitochondrial; ” in the associated disorder column, change “ 1° biliary cholangitis ” to “ 1° biliary cirrhosis. ”
131	Spore-forming bacteria	In the first sentence of column 2, change the sentence to read, “Some gram (+) bacteria can form spores [A] when nutrients are limited.”
154	<i>Pneumocystis jirovecii</i>	In the second paragraph, change “dapson (prophylaxis only)” to “dapson (prophylaxis as single agent, or treatment in combination with TMP).”

216	Scar formation*	In the keloid column of the collagen synthesis row, delete “disorganized” so the text reads “↑↑↑ (types I and III collagen)”
283	Splitting	In the illustration for Normal splitting, expiration, bring the blue and red lines for A2 and P2 closer together.
296	Hypertension	Change text to read, “Defined as persistent systolic BP \geq 130 mm Hg and/or diastolic BP \geq 80 mm Hg.” This statement aligns with ACC/AHA guidelines published late 2017.
417	Blood transfusion therapy*	In the clinical use column of the fresh frozen plasma/prothrombin complex concentrate row, delete “DIC.”
427	Antimetabolites*	In the table’s footnote, add the following text: “ ^a All are S-phase specific except cladribine, which is cell cycle nonspecific.”
475	Neural tube defects	In the meningocele row, delete the sentence “Associated with spina bifida cystica.”
524	Horner syndrome	Change the second bullet from the bottom in column 2 to read “2nd neuron: stellate ganglion compression by Pancoast tumor.”
525	CN III, IV, VI palsies*	In 3rd bullet of column 2, change “PCA aneurysm” to “PCom aneurysm.”
585	Urinary tract infection (acute bacterial cystitis)	Delete (acute bacterial cystitis) from the fact title.
631	Benign breast disease	Change the first sentence from “Most common in premenopausal women <35 years old” to “Most common in premenopausal women 20-50 years old.”

*New errata addition since the March 20, 2018 publication.